Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.65 is 56% above its 5-year average of -1.50, near the high end of its 5-year range (-10.75–-0.65).
As of the fiscal period ended Tuesday, June 30, 2026. 15.03% above its 12-month average of -0.77.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.65.
DEBT TO EQUITY RATIO
-0.65
DEBT TO EQUITY RATIO AVG TTM
-0.77
DEBT TO EQUITY RATIO AVG 3Y
-1.05
DEBT TO EQUITY RATIO AVG 5Y
-1.50
DEBT TO EQUITY RATIO AVG 10Y
-0.49
DEBT TO EQUITY RATIO AVG 15Y
-0.39
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.03%
CURRENT VS 3Y AVG
+37.78%
CURRENT VS 5Y AVG
+56.32%
CURRENT VS 10Y AVG
-33.65%
CURRENT VS 15Y AVG
-66.21%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
-602.97%
vs the sector median at left
Karyopharm Therapeutics Inc.
Market Cap
$14.58M
Debt to Equity Ratio
-0.65
TTM Avg
-0.77
3Y Avg
-1.05
5Y Avg
-1.50
Market Cap
$13.41M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.03
5Y Avg
0.20
Market Cap
$15.04M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$13.88M
Debt to Equity Ratio
0.11
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$15.30M
Debt to Equity Ratio
1.28
TTM Avg
0.21
3Y Avg
0.13
5Y Avg
0.09
Market Cap
$15.75M
Debt to Equity Ratio
6.30
TTM Avg
0.13
3Y Avg
0.74
5Y Avg
0.48
Market Cap
$13.06M
Debt to Equity Ratio
0.05
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $14.58M | -0.65 | -0.77 | -1.05 | -1.50 |
| Vyome Holdings, Inc. (HIND)vs › | $13.41M | 0.00 | 0.01 | 0.03 | 0.20 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.88M | 0.11 | 0.01 | 0.01 | 0.02 |
| IN8bio, Inc. (INAB)vs › | $13.67M | 0.12 | 0.22 | 0.23 | 0.16 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | 1.28 | 0.21 | 0.13 | 0.09 |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.11 | 0.86 | 0.69 | 0.45 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | 6.30 | 0.13 | 0.74 | 0.48 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.06M | 0.05 | 0.04 | 0.04 | 0.03 |
| Dare Bioscience, Inc. (DARE)vs › | $12.46M | N/A | 0.93 | 0.49 | 0.33 |
Debt/Equity
-0.65
Current Ratio
0.79
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.65 |
| 2026-03-31 | -0.87 |
| 2025-12-31 | -0.80 |
| 2025-09-30 | -0.73 |
| 2025-06-30 | -0.80 |
| 2025-03-31 | -0.91 |
| 2024-12-31 | -1.05 |
| 2024-09-30 | -1.22 |
| 2024-06-30 | -1.48 |
| 2024-03-31 | -1.04 |
| 2023-12-31 | -1.30 |
| 2023-09-30 | -1.77 |
| 2023-06-30 | -2.50 |
| 2023-03-31 | -3.95 |
| 2022-12-31 | -10.75 |
| 2022-09-30 | -1.28 |
| 2022-06-30 | -1.55 |
| 2022-03-31 | -2.17 |
| 2021-12-31 | -2.27 |
| 2021-09-30 | -1.44 |
| 2021-06-30 | -2.18 |
| 2021-03-31 | -4.58 |
| 2020-12-31 | 2.59 |
| 2020-09-30 | 1.55 |
| 2020-06-30 | 0.98 |
| 2020-03-31 | 0.76 |
| 2019-12-31 | 2.51 |
| 2019-09-30 | 2.06 |
| 2019-06-30 | 1.48 |
| 2019-03-31 | 0.99 |
| 2018-12-31 | 0.56 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 0.00 |
| 2012-09-30 | 0.00 |
